Clear and accurate understanding of diversity in antibody complementarity-determining regions (CDRs) is critical for antibody discovery and engineering. Previous observations of antibody CDR-H3 diversity were based on analyzing available antibody sequences in the public databases. The results may not accurately reflect that of natural antibody repertoire due to erroneous species annotation and the presence of man-made CDR loop diversity in public antibody sequence databases. In this study, in a precisely controlled germline context, we explored the relationship between amino acid composition and CDR-H3 length using 5518 unique productively rearranged human VH3-23*01 gene sequences. CDR-H3 length-dependent usage of the Cys-X n -Cys motif is reported here.
Introduction
Antibody complementarity-determining regions (CDRs), including six hypervariable loops, define the antibody-antigen recognition interface. Human antibody CDR-H3 regions, generally considered to be the most important CDR for antigen binding (Barrios et al., 2004; Kunik and Ofran, 2013; Sela-Culang et al., 2013) , are characterized far less accurately (Zemlin et al., 2003; Schroeder, 2006; Shi et al., 2014) due to the tremendous diversity in the antibody repertoire. Precise characterization of the CDR-H3 diversity, vital for a better understanding of antibody-antigen interaction, makes it possible to fully recapitulate the human antibody repertoire for in vitro therapeutic antibody development.
Amino acid distribution and variability by position in CDR-H3 had been previously analyzed (Zemlin et al., 2003; Schroeder, 2006; Shi et al., 2014) in both human and mouse using antibody variable region sequences obtained from public databases like Kabat and the International ImMunoGeneTics (IMGT) database. Even though all redundant, ambiguous, incomplete or non-functional sequences were filtered out in previous analysis (Zemlin et al., 2003; Shi et al., 2014) , germline or CDR-H3 length-specific amino acid distribution and variability in natural human antibody repertoire still could not be fully revealed due to the following reasons. First, species annotation errors were reported in public antibody sequence databases. Martin and Rees (2016) reported two major sources of errors in the public antibody databases in an antibody humanization study. On some occasions, chimeric antibodies were annotated as Homo sapiens even though they contain non-human derived variable domains. Humanized antibodies, where CDRs and key back mutations are generated from non-human species, are generally annotated as Homo sapiens (Martin and Rees, 2016) . Due to such erroneous species annotation, non-human derived CDR-H3 sequences were likely included as human in previous analysis (Zemlin et al., 2003; Shi et al., 2014) . Second, the germline gene usage in sequences collected from public antibody sequence databases could not fully recapitulate that of the natural human antibody repertoire. Shi et al. (2014) reported coverage of 52 (out of 71) human IGHV genes in their analysis. However, some commonly used Heavy-chain-variable (VH) germline such as IGHV1-2 and IGHV4-59/61 (Glanville et al., 2009; Finlay and Almagro, 2012) were significantly under-represented in their data set (Shi et al., 2014) . Last, the presence of artificial CDR-H3 sequences, the effect of which has yet to be determined, in the public antibody sequence databases. These antibodies are largely selected from synthetic antibody libraries using in vitro display technologies (Benhar, 2007; Finlay and Almagro, 2012; Shim, 2015) . Man-made CDR-H3 loop diversity was introduced either by amino acid randomization using degenerate codons (Griffiths et al., 1993) or by TRIM technology (Virnekas et al., 1994) . Overall, erroneous species annotation and the presence of man-made CDR loop diversity in public antibody sequence databases may have contributed to a biased and potentially misleading analysis, especially when such analysis serves as a foundation for antibody library design or for humanization design (Martin and Rees, 2016) .
To fully understand the correlation between human CDR-H3 length and amino acid usage distribution, we analyzed 5518 productively rearranged full VH3-23*01 variable sequences, one of the most commonly used variable regions in the human immune repertoire (Brezinschek et al., 1995) . Luckily, such a data set for bioinformatics analysis is available from previous studies (European Molecular Biology Laboratory accession nos. AM076988-AM083316) (OhmLaursen et al., 2006; Ohm-Laursen and Barington, 2007; Wei et al., 2015) . Out of 5670 productive rearrangements of IGHV3-23*01 rearranged to predominantly IGHJ4 and IGHJ6 (Ohm-Laursen and Barington, 2007), we identified 5518 full VH3-23*01 variable sequences that are free of sequence ambiguity at the CDR or framework regions. The CDR-H3 length (positions 105-117 per IMGT and 95-102 per Kabat) varied from 2 to 33 amino acid residues, with a mean length of 14.84 residues, which is consistent with previous observations (Wu et al., 1993; Zemlin et al., 2003; DeKosky et al., 2016) . The CDR3-H3 length follows a Gaussian distribution pattern (Wu et al., 1993; Zemlin et al., 2003; DeKosky et al., 2016) (Fig. 1) , with a prevalence of 12.16 and 10.18% for CDR-H3s of 12 and 14 amino acid residues in length, respectively. These observations, indicative of faithful recapitulation of human IGHV3-23*01 repertoire, validated this data set for further analysis.
Amino acid residues in the CDR loops contribute directly to the antibody-antigen recognition interface (Hardiman, 2012; Hou et al., 2016) . Therefore, it is important to understand amino acid composition distribution and variability by position in antibody CDRs, especially CDR-H3. Here, we calculated the amino acid composition in CDR-H3 (95-102 per Kabat) and corresponding germlineencoded portion (1-94 per Kabat) of 5518 human VH3-23*01 sequences ( Fig. 2A) . The three most frequently used amino acid residues, tyrosine (Y), glycine (G) and aspartic acid (D), accounted for 42.14% of total amino acid residues in CDR-H3 region. In contrast, these three amino acid residues only accounted for 19.37% of total amino acid residues in the germline-encoded portion. This observation suggests that Y, D and G residues are critical components at the antibody-antigen recognition interface, possibly by making direct contacts with antigen. For amino acid composition analysis samples size used here, e.g,~506 408 amino acids for the VH3-23*01 germline-encoded portion and 76 932 for the CDR-H3, the chisquared test P-value will be extremely low and thus always highly significant even with only slight change. In light of this, the confidence interval of ratio (based on approximately normal distribution of natural log of ratio) is used to evaluate the relative change between CDR-H3 and VH3-23*01 germline-encoded portion. The Y residue accounted for 17.50% of total amino acid residues in CDR-H3 region, which is over 3-fold change from 6.52% in the germline-encoded portion. High prevalence of Y may be partially contributed by predominant rearrangement with human IGHJ4 and IGHJ6 in this data set (Ohm-Laursen and Barington, 2007) . Same (>3-fold increase in CDR-H3) was observed for aspartic acid (D) and histidine (H). Over 2-fold increase in CDR-H3 was observed for methionine (M). In contrast, 3-fold less of glutamine (Q) and lysine (K) and 2-fold less of alanine (A), glutamic acid (E) and leucine (L) were observed in CDR-H3 than in VH3-23*01 germlineencoded portion. Ratio between negatively charged residues (D and E) and positively charged residues (R and K) was also determined and very significant difference was observed in charged residues composition between CDR-H3 and VH3-23*01 germline-encoded portion ( Fig. 2B . paired t-test; P < 0.0001). As shown in Fig. 2B , there was a constantly low DE/RK ratio in the VH3-23*01 germline-encoded portion (0.83 ± 0.02). In CDR-H3 loops, the DE/ RK ratio is very significantly increased (2.80 ± 0.24). Such a high DE/RK ratio may explain the overall negatively charged nature of CDR-H3 at pH7.0 (Fig. 2D) . Interestingly, Zhao and Li, 2010 analyzed 82 antibody-antigen complexes and identified the top 10 most frequent associations from antibody-antigen interacting complexes. Six of the 10 most frequent associations involved positively charged R and K residues in antigenic epitopes (Zhao and Li, 2010) . High R and K frequency was also reported in another study involving 106 linear B cell epitopes, which suggests it a focusing common feature in diverse epitope groups (Kozlova et al., 2015) .
CDR-H3 length-dependent changes in amino acid composition were previously investigated (Zemlin et al., 2003) when CDR-H3 from all germlines were included in the analysis. To determine the relationship between CDR-H3 loop length and amino acid composition in a controlled framework context, we calculated frequencies of individual amino acid residues. To minimize bias introduced by low sample numbers, we only included 5235 sequences in our analysis. The CDR-H3 length varied from 8 to 23 amino acid residues. As shown in Fig. 2C , when CDR-H3 length increased, the frequency of tyrosine residue steadily increased from 11.26% in CDR-H3 of (B) Difference in DE/RK ratio between CDR-H3 and VH3-23*01 germline-encoded portion. Statistical significance analysis was performed using paired t-test, P < 0.0001; Error bar indicates standard deviation among different CDR-H3 groups. (C) CDR-H3 length-dependent amino acid composition distribution in CDR-H3 loops. Statistical significance analysis of each amino acid composition distribution across different CDR-H3 length groups was performed using Pearson's Chi-square test and was described in the text. (D) The distribution of hydrophilic/hydrophobic ratio, GRAVY score and net charge at pH7.0 in CDR-H3 loops across different CDR-H3 length groups. Due to high variation within the same CDR-H3 length group, statistical significance analysis was not performed.
eight amino acid residues length to 22.54% in CDR-H3 of 23 amino acid residues length (Pearson's Chi-square test, P < 0.0001). This finding is consistent with previous observations (Zemlin et al., 2003; Zhai et al., 2011; Finlay and Almagro, 2012; Ramaraj et al., 2012) . The frequency of methionine (M, 2.06-4.30%; P < 0.0001) and valine (V, 5.91-8.22%; P < 0.001) also gradually increased with CDR-H3 length. The frequency of aspartic acid gradually decreased from 15.11 to 9.74% when CDR-H3 length increased from 8 to 23 amino acid residues (P < 0.0001). Similarly, the frequency of alanine (A, 5.08-3.73%; P < 0.0001), arginine (R, 4.81-2.93%; P < 0.05), leucine (L, 5.77-3.88%; P > 0.05), phenylalanine (F, 4.81-3.02%; P < 0.0001), asparagine (N, 3.16-1.70%; P < 0.0001), glutamic acid (E, 3.85-2.13%; P < 0.001) and isoleucine (I, 2.34-1.94%; P > 0.05) residues steadily decreased, albeit at a much slower pace, when CDR-H3 loop length increased. In contrast to a steady decrease of glycine residue usage reported by Zemlin et al. (2003) , the frequency of glycine residue remained almost constant at~13% in our analysis (P > 0.05). The frequency of serine (S), proline (P), threonine (T), tryptophan (W), glutamine (Q), histidine (H) and lysine (K) residues also remained almost unchanged. The relationship between CDR-H3 length and hydrophilic/hydrophobic ratio was also determined. The lowest hydrophilic/hydrophobic ratio at 1.93 was observed in CDR-H3 loops of 14 amino acid residues length (Fig. 2D) . When CDR-H3 length increased from 14 amino acid residues, the hydrophilic/hydrophobic ratio steadily increased from 1.93 to 2.19. The grand average of hydropathy (GRAVY) was determined to measure the hydrophobicity or hydrophilicity of CDR-H3 loops (Fig. 2D) . As CDR-H3 length increased from 8 to 23 amino acid residues, the GRAVY score increased from −0.74 to −0.39, which is consistent with the observation of steady increase of the hydrophilic/ hydrophobic ratio. It is notable that there was huge variation in GRAVY score and net charge at pH7.0 within the same CDR-H3 length group, which made it difficult to determine if the changes we observed in GRAVY and net charge were statistically significant.
To further characterize amino acid variability in CDR-H3, we calculated individual amino acid frequency by position (positions 105-117 per IMGT and 95-102 per Kabat). Very limited amino acid variability at IMGT positions 114-117 and significantly increased prevalence of tyrosine residue at IMGT positions 112.3-113 (Fig. 3) were observed. This is likely due to the predominant rearrangements with human IGHJ4 and IGHJ6. Glycine accounted for 53.58% of all residues at IMGT position 114. Such limited variability at IMGT , from the third quartile to the first quartile. The IQR is represented by the height of the box. The median is shown by a line that divides the box. The whiskers extend from the end of the box to the outmost data point that falls within the range (1.5*IQR below the first quartile, 1.5*IQR above the third quartile). If a data value is less than 1.5*IQR below the first quartile or greater than 1.5*IQR above the third quartile, it is shown as an outlier point. IQR, interquartile range. position 114 could not be revealed when Kabat numbering was used in this analysis (data not shown). The pattern of CDR-H3 lengthdependent changes, other than a steady increase of tyrosine usage when CDR-H3 loops got longer, showed only partial overlap with previous reports (Zemlin et al., 2003; Ramaraj et al., 2012; Burkovitz et al., 2014) . For example, the dominance of T, Y and R amino acid residues in the antibody paratope-containing surface was reported after analyzing 53 non-redundant structures of antigen-antibody complexes (Ramaraj et al., 2012) . In our study, Y, G and D amino acids residues dominated the antibody-antigen interface. Since only one VH germline (VH3-23*01) was included in our analysis, CDR-H3 lengthdependent changes in amino acid composition could be specific to VH3-23 germline. This needs to be determined when more sequences from other VH germlines are available.
It is notable that the frequency of cysteine increased significantly from 0.14 to 1.65% when CDR-H3 length increased from 8 to 23 amino acid residues ( Fig. 2B; Pearson's Chi-square test, P < 0.0001). Cysteine, even though rarely observed in mouse antibody CDRs, plays a critical role in the antibody structure and function of human (Zemlin et al., 2003) , non-human primate (Schroeder, 2006) , bovine (Berens et al., 1997; Wang et al., 2013) , avian (Butler et al., 2006) (Reynaud et al., 1991) , shark (Dooley and Flajnik, 2006; Smith et al., 2012) and camelid (Harmsen et al., 2000; De Genst et al., 2006) . Out of 5309 rearranged IGHV3-23*01 antibody heavy chain variable region sequences, 663 (12.49%) sequences with a CDR-H3 length from 7 to 23 amino acid residues contained one or more cysteine residue(s) in the CDR-H3 region, including 186 (3.50%) sequences contained a single cysteine residue and 468 (8.82%) contained two cysteine residues. Six and three CDR-H3 sequences were observed to have three and four cysteine residues, respectively. In 468 CDR-H3 sequences containing two cysteine residues, the two cysteine residues were separated by 0-11 amino acid residues. In 435 out of 468 sequences (92.95%), the paired cysteine residues were separated by three (52, 11.11%) or four (383, 81.84%) amino acid residues (see Supplementary data, Table S1 ). The consensus sequence of the Cys-X 3 -Cys motifs is CGGDC, while the consensus sequence of the Cys-X 4 -Cys motifs is CS(S/G)(T/G)SC. The Cys-X 4 -Cys motifs were predominantly encoded by the human IGHD2 (D2-2, D2-8 and D2-15) germline family, which is consistent with previous studies (Zemlin et al., 2003) . Zemlin et al. (2003) reported that the frequency of cysteine in human CDR-H3 loops varied by length. The frequency of cysteine in CDR-H3 longer than 15 amino acid residues was~2.5 times higher than that of CDR-H3 shorter than 15 amino acid residues (Zemlin et al., 2003) . To investigate how the frequency of cysteine was affected by the length of CDR-H3, we determined the frequency of a single cysteine and the frequency of the Cys-X n -Cys motif in CDR-H3 with length varying from 7 to 23 amino acid residues (Fig. 4A) . The presence of cysteine was rarely observed when CDR-H3 length is shorter than nine amino acid residues. Cysteine residues began to emerge in CDR-H3 loops of 10 amino acid residues length. They predominantly existed as single unpaired cysteine residues (data not shown). The presence of Cys-X 4 -Cys motif, albeit at a very low frequency (0.5%), was first observed in CDR-H3 of 11 amino acid residues length. As the length of CDR-H3 increased, the frequency of single cysteine residue gradually decreased from 6.42% in CDR-H3 of 10 amino acid residues length to 1.05% in CDR-H3 with length of 23 amino acid residues (Fisher's exact test, P = 0.018). In contrast, the frequency of the Cys-X n -Cys motif increased very significantly from 0.92% in CDR-H3 with length of 10 amino acid residues to 18.48% in CDR-H3 with length of 23 amino acid residues (Fisher's exact test, P < 0.0001) (Fig.4A) . In VH3-23 antibodies with CDR-H3 length over 20 amino acid residues, one out of every five antibodies contained an intra-CDR disulfide bridge. The increased frequency of the Cys-X n -Cys motif in antibodies with longer CDR-H3 indicates a critical structural role of intra-CDR3 disulfide bridge(s). Possibly the intra-CDR disulfide bridge(s) stabilizes the long CDR-H3 loops by preventing them from being folded back to the VH/lightchain-variable (VL) interface (Zabetakis et al., 2014) . Such intra-CDR disulfide bridge is represented by CAP256-VRC26.25, a potent V1V2-directed HIV-1 broadly neutralizing antibody (Protein Data Bank [PDB]: 5DT1) (Doria-Rose et al., 2016) , and VRC08C, a gp120-directed HIV-1 broadly neutralizing antibody (PDB: 4XNY) (Wu et al., 2015) . In both cases, the disulfide bridge(s) stabilizes the CDR-H3 loops so that the loops are projected outward in solvent exposed phase (Fig. 4B) . Another form of disulfide bridge was formed between CDR-H1 and CDR-H3, as represented by another HIV-1 broadly neutralizing antibody NIH45-46 (PDB: 3U7W) (Diskin et al., 2011) (Fig. 4B) . Disulfide bridge between CDR-H3 and CDR-H2 was reported in camelid VH-domain-only (VHH) antibodies (Conrath et al., 2003) . Such disulfide bridge was also observed in our analysis (Accession #: AM080992.1). Very intriguingly, intra-CDR and inter-CDR disulfide bridges were frequently reported in human broadly neutralizing antibodies that neutralize viral infection like HIV-1 (PDB: 3SE8, 4OLU, 4ORG, 4XNY, 5DT1) (Wu et al., 2011 (Wu et al., , 2015 DoriaRose et al., 2014 DoriaRose et al., , 2016 Rudicell et al., 2014) , human influenza virus (PDB: 3FKU, 4O58, 5A3I) (Sui et al., 2009; Lee et al., 2014; Xiong et al., 2015) , human hepatitis C virus (PDB: 4MWF) (Kong et al., 2013) and human cytomegalovirus (PDB: 3EYO) (Thomson et al., 2008) . These findings suggest the presence of Intra-CDR or inter-CDR disulfide bridges could contribute to unique-binding profiles such as high affinity and broad specificity toward difficult to reach epitopes (Ramsland et al., 2001; Almagro et al., 2012; Wu et al., 2015; DoriaRose et al., 2016) and/or thermostability of antibodies (Conrath et al., 2003; Zabetakis et al., 2014) . Unpaired cysteine residues were also observed, especially in antibodies with CDR-H3 length of 10-16 amino acid residues (data not shown). Since we do not have paired light chain sequences in our analysis, we could not rule out the possibility of inter-chain disulfide bridge formation. These unpaired cysteine residues mainly existed in the V-D or D-J junctions (data not shown). Therefore, they are likely buried and solvent inaccessible.
Conclusion
In the context of a given framework VH3-23*01, we observed CDR-H3 length-dependent changes in amino acid composition, net charge distribution, limited amino acid variability at IMGT positions 114-117 and CDR-H3 length-dependent usage of the Cys-X 4 -Cys motif. CDR-H3 length-dependent usage of the Cys-X 4 -Cys motif suggests a critical functional/structural component of CDR-H3 diversity. The frequent presence of such functional/structural Cys-X 4 -Cys motifs in many broadly neutralizing antibodies against several human infectious agents of public health concern indicates that such conserved Cys-X 4 -Cys motifs are the results of hostpathogen coevolution. However, in the development of antibodybased therapeutics, antibodies with non-canonical disulfide bridge(s) were generally not considered as lead molecules because of concerns about poor drug-like properties, especially the long-term storage stability of the molecules. Further understanding of the Cys-X n -Cys motifs in the context of VH/VL pairing could help us to properly address the stability concerns, while maintaining the benefits of high potency/affinity, broad specificity, and targeting difficult to reach epitopes. Unfortunately, such unique-binding profiles could not be discovered when hybridoma is used as main source of antibody diversity as cysteine residues are rarely observed in mouse CDR-H3 loops (Zemlin et al., 2003) . Such knowledge could shed light on the next generation synthetic antibody library design so the man-made diversity could fully mimic that of natural human antibody repertoire, which would further enable novel, unique and differentiated biologics development.
Supplementary data
Supplementary data are available at Protein Engineering, Design & Selection online. Fig. 4 CDR-H3 length-dependent usage of cysteine and the Cys-X n -Cys motif in CDR-H3. (A) Increased frequency of the Cys-X n -Cys motif as CDR-H3 loop got longer. Statistical significance analysis was performed using Fisher's exact test, P < 0.0001; Reduced frequency of single, unpaired cysteine residue as CDR-H3 length increased from 10 to 23 amino acid residues. Statistical significance analysis was performed using Fisher's exact test, P = 0.018. (B) Representative intra-CDR disulfide bridge(s) (5DT1 and 4XNY) in CDR-H3 loops and inter-CDR disulfide bridge (3U7W) between CDR-H1 and CDR-H3. CDR-H3 loops (blue), CDR-H1 loop (gray) and disulfide bridges (magenta) are highlighted. More antibody structures containing intra-CDR and/or inter-CDR disulfide bridge(s) were described in the text. All VH3-23*01 sequences with one or more cysteine residue(s) in CDR-H3 were listed in Supplementary data, Table S1 .
